The Management of Testicular Seminomas, 1979

Abstract

The reported results from throughout the world of modern treatment of testicular seminoma are reviewed for the various clinical stages of disease. The three-year survival rate for 1,346 patients with Stage 1 and 2 disease is 91%. Since the review reveals considerable differences in staging methods, a clinically useful staging system is proposed. Treatment methods are described and discussed. Recommendations are made assuming that patients so treated are clinically evaluated for extent of disease before treatment with currently available techniques, including lymphangiography, CT scanning, perhaps ultrasonography, and serum marker determinations. Although the role of cytoreductive surgery in patients with seminoma, even bulky seminoma, now is limited, occasionally when laparotomy is done, debulking may also be helpful. Effective combination chemotherapy regimens have not been identified. The 28% three-year survival rate of patients with Stage 3 disease establishes the real need to identify such therapy. Finally, anaplastic seminoma is considered; a recent review by Percarpio indicates that this subtype perhaps is not unlike classical seminoma as far as stage distribution and prognosis is concerned.

Use of Contrast‐Enhanced Ultrasonography in Chronic Pathologic Canine Testes

“…The reason for this difference in findings between species is unknown, although there is a correspondence in the description of grey‐scale ultrasonographic features (Caldwell et al. ; Lock et al. ).…”

The VAB-6 regimen in the treatment of metastatic seminoma

“…3 In addition, 40% to 50% of patients with bulky abdominal metastases relapse after irradiation." Systemic chemotherapy has become a logical therapeutic alternative for such patients.…”

“…R of irradiation to areas of potential or actual lymph node metastases is the treatment of choice for patients with seminoma confined to the testis (Stage I) or to the testis and retroperitoneal lymph nodes (Stage 11), and the resultant overall cure rates are However, for the 5% to 10% of patients with testicular seminoma presenting with metastases beyond the retroperitoneal lymph nodes (Stage 111), 5-year survival with radiation therapy alone may be as low as 20%.i. 3 In addition, 40% to 50% of patients with bulky abdominal metastases relapse after irradiation." Systemic chemotherapy has become a logical therapeutic alternative for such patients.…”

Therapy in Stage I Non-Seminomatous Testicular Tumor

“…Some of them are commonly accepted as neces sary and effective measures such as irradiation of un disseminated seminoma [6,50], dissection of resectable retroperitoneal lymph node métastasés (RLND) of nonseminoma and chemotherapy of parenchymal métas tasés. In other cases, e.g.…”